Natreon, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Oct 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 21, 2027The maintenance fee for Indolealkylamino-withasteroid conjugates and method of use (US 9,084,800) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
- 1 fee due Apr 22, 2027The maintenance fee for Indolealkylamino-withasteroid conjugates and method of use (US 10,449,206) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
- 1 fee due Jun 10, 2027The maintenance fee for Use of terminalia chebula extract for treatment of osteoarthritis (US 10,500,240) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,206,757 | Composition of Ashwagandha and Indian Gooseberry In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 9,084,800 | Indolealkylamino-withasteroid conjugates and method of use In force · From the USPTO record | In force | From the USPTO record | |
| US 8,894,993 | Mitochondria-targeted antioxidants In force · From the USPTO record | In force | From the USPTO record | |
| US 9,393,281 | Composition of Beta-Glucan and Ashwagandha In force · High confidence | In force | High confidence | |
| US 8,962,576 | Compositions and Method for Improving Endothelial Function and Cardiovascular Health In force · High confidence | In force | High confidence | |
| US 10,449,206 | Indolealkylamino-withasteroid conjugates and method of use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,183,047 | Chromium-containing compositions in combination with Phyllanthus emblica and shilajit having synergistic effects for improving endothelial function and cardiovascular health In force · From the USPTO record | In force | From the USPTO record | |
| US 10,500,240 | Use of terminalia chebula extract for treatment of osteoarthritis In force · From the USPTO record | In force | From the USPTO record | |
| US 11,077,045 | Blood microperfusion to skin by Shilajit In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 9: 4 lapsed for an unpaid fee · 12 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 20 no status recorded